Here are six points:
1. Titan Spine experienced more than 50 percent sales revenue growth January 1 through June 30, 2015 compared to the same timeframe in 2014.
2. The growth is attributed to the increasing demand for the company’s titanium spinal interbody fusion devices.
3. Titan Spine expects to surpass $32 million in sales and implant more than 10,000 devices in 2015.
4. The surgeon retention rate increased to about 85 percent.
5. The company had more than 330 surgeon customers in Q1 and Q2 in 2015.
6. Titan Spine launched the Endoskeleton TL lateral device in Q1, 2015.
“The first six months of 2015 have seen the greatest accelerated sales growth and surgeon adoption rate in Titan Spine’s history,” said Kevin Gemas, president of Titan Spine. “Not only is the interbody fusion market gravitating toward titanium, but specifically toward titanium devices like ours…”
More articles on devices:
5 observations on Fiagon, Entellus Medical bringing image guidance technology to US
NuVasive to take part in investor event: 4 key notes
ConforMIS Q2 revenue hits $19.2M, net loss at $10.9M: 8 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
